SecBot SecBot
8-K ·Filed May 15, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-225317
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The data is incremental and consistent with previously announced December 2025 topline results. No new regulatory catalyst or financial update, monitor for FDA meeting outcomes and Phase 3 initiation plans as the next value drivers.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$114.24
T+0 close · May 15, 2026 · via day close
Latest settled
+35.07%
T+60 · $154.30
Vs SPY
+30.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $114.24entry
  2. T+1 · 6mo ago −8.04%α −7.98% · $105.05
  3. T+5 · 6mo ago −0.22%α −1.18% · $113.99
  4. T+20 · 5mo ago +1.99%α −0.13% · $116.51
  5. T+60 · 3mo ago +35.07%α +30.55% · $154.30

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venous malformations, presented at the SID annual meeting. The data showed 100% of patients with baseline bleeding achieved statistically significant improvement on the cVM-IGA Bleeding scale at Week 12 (+2.5 points, p=0.003). This is a clinical-stage biotech update with no financial figures or regulatory milestones, the filing is a routine data readout disclosure.

Key Facts

  • Phase 2 TOIVA trial data presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
  • 100% of patients with bleeding at baseline (n=4) showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (+2.5 point improvement; p=0.003)
  • 100% of patients with bleeding at baseline reported being satisfied or very satisfied with QTORIN rapamycin on the Treatment Satisfaction Questionnaire for Medication at Week 12
  • QTORIN rapamycin has potential to become first FDA-approved therapy for an estimated >75,000 individuals with cutaneous venous malformations in the U.S.
  • TOIVA is a single-arm, open-label, baseline-controlled Phase 2 trial with 12-week efficacy evaluation and 12-week extension period

Financial Impact

No financial figures disclosed in the filing. Clinical-stage company with no approved products or reported revenue.

Risk Factors

  • Phase 2 data from a single-arm, open-label trial with only 4 patients evaluable for the bleeding endpoint, limited statistical power
  • QTORIN rapamycin is investigational and not yet FDA-approved for any indication
  • Clinical-stage biotech with no approved products or revenue, dependent on future capital raises

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-225317
Document: pvla-ex99_1.htm0001193125-26-225317
Document: 0001193125-26-225317-index-headers.html0001193125-26-225317
Document: 0001193125-26-225317-index.html0001193125-26-225317
Document: 0001193125-26-225317.txt0001193125-26-225317

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026